Efficacy and Safety of Retatrutide, a Novel GLP-1, GIP, and Glucagon Receptor Agonist for Obesity Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Abdrabou Abouelmagd A
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed for the management of type 2 diabetes mellitus and, in specific cases, for weight management
& nler-Gmta, A
While the potential for major weight loss is high, the total amount an individual will lose varies on a case-by-case basis
51,113 Based on indications for the drug industry released by the FDA in 2019, candidate drugs achieving histological outcomes can be conditionally approved, and there remains a necessity to refine the assessment of clinical outcomes in the future
Endocrine (2020) 68(3):51825